Skip to main content
. Author manuscript; available in PMC: 2017 Oct 4.
Published in final edited form as: Cell Rep. 2016 Oct 4;17(2):609–623. doi: 10.1016/j.celrep.2016.09.021

Figure 4. Cholesterol and serine-glycine pathways are essential for maintaining neuroblastoma sphere-forming cells.

Figure 4

(A) Growth assays of neuroblastoma sphere-forming cells treated with DMSO, increasing concentrations of Simvastatin (Simva) or 2 μM Fluvastatin (Fluva). Error bars represent SD (n = 4). Data were analyzed by two-way ANOVA with p values indicated.

(B) Growth assays of neuroblastoma sphere-forming cells treated with DMSO and Simva with or without mevalonate (Meval). Error bars represent SD (n = 4). Data were analyzed by two-way ANOVA with the p value indicated.

(C) Tumor transplantation assay of neuroblastoma sphere-forming cells treated with DMSO or 5 μM Simva for 24 hours. Tumor weight was analyzed by scatter plot with horizontal lines indicating the mean.

(D) qRT-PCR analysis of Phgdh mRNA levels in neuroblastoma sphere-forming cells infected with lentiviruses expressing shRNA against GFP or Phgdh. Error bars represent SD (n = 3).

(E) Growth assays of neuroblastoma sphere-forming cells without or with Phgdh knockdown. Error bars represent SD (n = 4). Data were analyzed by two-way ANOVA with p values indicated.

(F) Tumor transplantation assay of neuroblastoma sphere-forming cells without or with Phgdh knockdown. Tumor weight was analyzed by scatter plot with horizontal lines indicating the mean.

**p < 0.01, ***p < 0.001. See also Figure S4.